Moderna Moves Forward With Second HIV Vaccine Trial
Moderna Inc (NASDAQ:MRNA) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574). The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble…
Benzinga ·
Reason
The Conversation
The Independent UK
International Business Times UK
Benzinga
Medical Daily
Roll Call
Al Jazeera
Salon
The Guardian - US
Tribune News Service
Axios
